These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 12709013)

  • 41. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
    Qin YR; Qiao JJ; Chan TH; Zhu YH; Li FF; Liu H; Fei J; Li Y; Guan XY; Chen L
    Cancer Res; 2014 Feb; 74(3):840-51. PubMed ID: 24302582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.
    Samuel CE
    J Biol Chem; 2019 Feb; 294(5):1710-1720. PubMed ID: 30710018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1.
    Herbert A; Rich A
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12132-7. PubMed ID: 11593027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs.
    Walkley CR; Li JB
    Genome Biol; 2017 Oct; 18(1):205. PubMed ID: 29084589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics.
    Nakano M; Nakajima M
    Pharmacol Ther; 2018 Jan; 181():13-21. PubMed ID: 28716651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RNA editing underlies genetic risk of common inflammatory diseases.
    Li Q; Gloudemans MJ; Geisinger JM; Fan B; Aguet F; Sun T; Ramaswami G; Li YI; Ma JB; Pritchard JK; Montgomery SB; Li JB
    Nature; 2022 Aug; 608(7923):569-577. PubMed ID: 35922514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADAR2 A-->I editing: site selectivity and editing efficiency are separate events.
    Källman AM; Sahlin M; Ohman M
    Nucleic Acids Res; 2003 Aug; 31(16):4874-81. PubMed ID: 12907730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.
    Hartwig D; Schütte C; Warnecke J; Dorn I; Hennig H; Kirchner H; Schlenke P
    J Viral Hepat; 2006 Mar; 13(3):150-7. PubMed ID: 16475990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K; Xu LD; Lagergren J; Öhman M
    Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutières-syndrome-like encephalopathy.
    Nakahama T; Kato Y; Shibuya T; Inoue M; Kim JI; Vongpipatana T; Todo H; Xing Y; Kawahara Y
    Immunity; 2021 Sep; 54(9):1976-1988.e7. PubMed ID: 34525338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining the functions of adenosine-to-inosine RNA editing through hematology.
    Heraud-Farlow JE; Chalk AM; Walkley CR
    Curr Opin Hematol; 2019 Jul; 26(4):241-248. PubMed ID: 31033705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.
    Chung H; Calis JJA; Wu X; Sun T; Yu Y; Sarbanes SL; Dao Thi VL; Shilvock AR; Hoffmann HH; Rosenberg BR; Rice CM
    Cell; 2018 Feb; 172(4):811-824.e14. PubMed ID: 29395325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease.
    Vlachogiannis NI; Sachse M; Georgiopoulos G; Zormpas E; Bampatsias D; Delialis D; Bonini F; Galyfos G; Sigala F; Stamatelopoulos K; Gatsiou A; Stellos K
    J Mol Cell Cardiol; 2021 Nov; 160():111-120. PubMed ID: 34302813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS; Ben-Asher N; Lamm AT
    Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased adenosine-to-inosine RNA editing in rheumatoid arthritis.
    Vlachogiannis NI; Gatsiou A; Silvestris DA; Stamatelopoulos K; Tektonidou MG; Gallo A; Sfikakis PP; Stellos K
    J Autoimmun; 2020 Jan; 106():102329. PubMed ID: 31493964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RNA editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells.
    Omata Y; Okawa M; Haraguchi M; Tsuruta A; Matsunaga N; Koyanagi S; Ohdo S
    J Biol Chem; 2022 Aug; 298(8):102184. PubMed ID: 35753353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
    Nakano M; Fukami T; Gotoh S; Nakajima M
    J Biol Chem; 2017 Mar; 292(12):4873-4884. PubMed ID: 28188287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure.
    Solomon O; Di Segni A; Cesarkas K; Porath HT; Marcu-Malina V; Mizrahi O; Stern-Ginossar N; Kol N; Farage-Barhom S; Glick-Saar E; Lerenthal Y; Levanon EY; Amariglio N; Unger R; Goldstein I; Eyal E; Rechavi G
    Nat Commun; 2017 Nov; 8(1):1440. PubMed ID: 29129909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research.
    Kwak S; Nishimoto Y; Yamashita T
    RNA Biol; 2008; 5(4):193-7. PubMed ID: 18971634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADAR RNA editing in human disease; more to it than meets the I.
    Gallo A; Vukic D; Michalík D; O'Connell MA; Keegan LP
    Hum Genet; 2017 Sep; 136(9):1265-1278. PubMed ID: 28913566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.